Evidence map›Paper›PMID 40885854›Full record

ArticleOncogene2025

LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.

Antonella Bacchiocchi, Michael Mak, Zerin Mahzabin Khan, Xiangyu Gong, Mario Sznol, Zhenkun Na, Haomiao Su, Lok Hei Chan, Qin Yan, Dejian Zhao and 4 more

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Antonella BacchiocchiDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
Michael MakYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Zerin Mahzabin KhanDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0001-6033-2013
Xiangyu GongDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0003-4033-9570
Mario SznolDepartment of Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4137-9662
Zhenkun NaDepartment of Chemistry, Yale University, New Haven, CT, USA.
Haomiao SuDepartment of Chemistry, Yale University, New Haven, CT, USA.ORCID 0000-0001-6232-6725
Lok Hei ChanDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Qin YanYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-4077-453X
Dejian ZhaoYale Center for Genome Analysis, Yale University, New Haven, CT, USA.
Ryland D MortlockDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0001-9666-4394
James KnightYale Center for Genome Analysis, Yale University, New Haven, CT, USA.
Sarah A SlavoffDepartment of Chemistry, Yale University, New Haven, CT, USA. sarah.slavoff@yale.edu.ORCID 0000-0002-4443-2070
Ruth HalabanDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, USA. ruth.halaban@yale.edu.ORCID 0000-0001-8451-1964

Funding

Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9M
Melanoma Research Alliance (MRA) NoneNCI NIH HHS P50 CA121974U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA121974
6 · The paper itself

Abstract

Leucine zipper like transcription regulator 1 (LZTR1) is amplified in acral melanomas, is required for melanocytes and melanoma cell proliferation, and it induces anchorage-independent growth, by yet unknown mechanisms. We therefore performed comprehensive studies to identify its activity in melanomas employing proximity biotinylation and co-immunoprecipitation combined with LC-MS/MS proteomics and molecular characterization. The results show that LZTR1 regulates the ubiquitin proteasome system in melanoma cells and also associates with actin-related proteins and actin cytoskeleton organization. Its downregulation suppresses the protective effect of the autophagy-initiating ULK1 and AMBRA1, regulators of normal cell survival and proliferation, and upregulates the sequestosome 1 (SQSTM1/p62), an autophagic cargo adapter which mediates selective degradation of ubiquitinated proteins. In contrast, overexpression of LZTR1 provides growth advantage under environmental stress, enhancing cell invasion, by activating ERBB3 receptor and its downstream targets PYK2 and SRC tyrosine kinases that regulate the cytoskeleton, actin organization, cell spreading, cell migration and adhesion. LZTR1 is a "safeguard" for melanoma cells under stress and its downregulation can be exploited for melanoma therapy.

Indexed as

ApoptosisMelanomaOncogenesTranscription FactorsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessTranscription Factors

Identifiers

PMID40885854
PMCPMC12500468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.